Comparing Nexentis Technologies (NASDAQ:NXTS) and Bristol Myers Squibb (NYSE:BMY)

Bristol Myers Squibb (NYSE:BMY) and Nexentis Technologies (NASDAQ:NXTS) are both healthcare companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, risk, valuation, dividends and profitability.

Profitability

This table compares Bristol Myers Squibb and Nexentis Technologies’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Bristol Myers Squibb	18.87%	66.90%	14.74%
Nexentis Technologies	N/A	-304.79%	-178.91%

Analyst Recommendations

This is a summary of current ratings and recommmendations for Bristol Myers Squibb and Nexentis Technologies, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Bristol Myers Squibb	1	10	12	2	2.60
Nexentis Technologies	1	0	0	0	1.00

Bristol Myers Squibb presently has a consensus target price of $67.06, suggesting a potential upside of 9.65%. Given Bristol Myers Squibb’s stronger consensus rating and higher probable upside, equities analysts plainly believe Bristol Myers Squibb is more favorable than Nexentis Technologies.

Insider & Institutional Ownership

76.4% of Bristol Myers Squibb shares are held by institutional investors. Comparatively, 61.2% of Nexentis Technologies shares are held by institutional investors. 0.1% of Bristol Myers Squibb shares are held by insiders. Comparatively, 6.5% of Nexentis Technologies shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

Valuation & Earnings

This table compares Bristol Myers Squibb and Nexentis Technologies”s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Bristol Myers Squibb	$49.19 billion	2.54	$7.05 billion	$4.54	13.47
Nexentis Technologies	$210,000.00	9.87	-$4.00 million	($96.07)	-0.01

Bristol Myers Squibb has higher revenue and earnings than Nexentis Technologies. Nexentis Technologies is trading at a lower price-to-earnings ratio than Bristol Myers Squibb, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Bristol Myers Squibb has a beta of 0.19, indicating that its share price is 81% less volatile than the S&P 500. Comparatively, Nexentis Technologies has a beta of 1.84, indicating that its share price is 84% more volatile than the S&P 500.

Summary

Bristol Myers Squibb beats Nexentis Technologies on 12 of the 15 factors compared between the two stocks.

About Bristol Myers Squibb

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company. Bristol-Myers Squibb Company was founded in 1887 and is headquartered in Princeton, New Jersey.

About Nexentis Technologies

N2OFF, Inc., an agri-food tech company, engages in the development and sale of eco-friendly green solutions for the food industry to enhance food safety and shelf life of fresh produce. Its products are based on proprietary blend of food acids combined with various oxidizing agent-based sanitizers and low concentrated fungicides for cleaning, sanitizing, and controlling pathogens on fresh produce that are safer for human consumption and extend their shelf life by reducing their decay. The company’s products include SavePROTECT or PeroStar, a processing aid for post-harvest application that is added to fruit and vegetable wash water; and SF3HS and SF3H, a post-harvest cleaning and sanitizing solution to control plant and foodborne pathogens. It also offers SpuDefender for controlling post-harvest potato sprouts; and FreshProtect to control spoilage-creating microorganisms on post-harvest citrus fruit. The company was formerly known as Save Foods, Inc. and changed its name to N2OFF, Inc. in March 2024. N2OFF, Inc. was incorporated in 2009 and is headquartered in Hod HaSharon, Israel.